Sonnet Bio Therapeutics Holdings, Inc. SONN
We take great care to ensure that the data presented and summarized in this overview for Sonnet BioTherapeutics Holdings, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in SONN
Top Purchases
Top Sells
About SONN
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.
Insider Transactions at SONN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 11
2025
|
John K. Cini Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+45.95%
|
-
|
|
Jul 11
2025
|
Susan Dexter Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+45.34%
|
-
|
|
Jul 11
2025
|
Richard T Kenney Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+46.05%
|
-
|
|
Jul 11
2025
|
Nailesh Bhatt Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+48.67%
|
-
|
|
Jul 11
2025
|
Donald J. Griffith Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+49.08%
|
-
|
|
Jul 11
2025
|
Lori Mc Neill Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+47.65%
|
-
|
|
Jul 11
2025
|
Stephen J Mcandrew Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+48.21%
|
-
|
|
Jul 11
2025
|
Raghu Rao Interim CEO |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+47.22%
|
-
|
|
Dec 11
2023
|
John Harry Cross Iii Chief Financial Officer |
SELL
Grant, award, or other acquisition
|
Direct |
1,452
-47.76%
|
-
|
|
Dec 11
2023
|
Richard T Kenney Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,271
+48.05%
|
-
|
|
Dec 11
2023
|
Pankaj Mohan Chairman, President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
7,554
+33.51%
|
-
|
|
Dec 11
2023
|
Donald J. Griffith Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
317
+45.81%
|
-
|
|
Dec 11
2023
|
John K. Cini Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,888
+47.15%
|
-
|
|
Dec 11
2023
|
Raghu Rao Interim CEO |
BUY
Grant, award, or other acquisition
|
Direct |
373
+13.67%
|
-
|
|
Dec 11
2023
|
Albert D. Dyrness Director |
BUY
Grant, award, or other acquisition
|
Direct |
373
+40.99%
|
-
|
|
Dec 11
2023
|
Lori Mc Neill Director |
BUY
Grant, award, or other acquisition
|
Direct |
373
+48.63%
|
-
|
|
Dec 11
2023
|
Susan Dexter Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,452
+46.91%
|
-
|
|
Dec 11
2023
|
Nailesh Bhatt Director |
BUY
Grant, award, or other acquisition
|
Direct |
373
+40.54%
|
-
|
|
Oct 27
2023
|
Pankaj Mohan Chairman, President and CEO |
BUY
Open market or private purchase
|
Direct |
34,375
+36.61%
|
-
|
|
Oct 27
2023
|
Raghu Rao Interim CEO |
BUY
Open market or private purchase
|
Direct |
15,625
+48.17%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 78K shares |
|---|